Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Lihua Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Immunity, Humoral, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang Province Public Welfare Technology Application Research Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite significant progress in vaccine development, especially in the fight against viral infections, many unexplored areas remain including innovative adjuvants, diversification of vaccine formulations, and research into the coordination of humoral and cellular immune mechanisms induced by vaccines. Effective coordination of humoral and cellular immunity is crucial in vaccine design. In this study, we used the spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or ovalbumin (OVA) as antigen models and CpG DNA (an activator of toll-like receptor 9, TLR9) as an adjuvant to prepare a multitargeted liposome (LIPO) vaccine. Once equipped with the ability to target lymph nodes (LN) and the endoplasmic reticulum (ER), the LIPO vaccine significantly enhances the cross-presentation ability of antigen-presenting cells (APCs) for exogenous antigens through the ER-associated protein degradation (ERSD) mechanism. Additionally, the vaccine could fine-tune the efficiency of ER-targeted antigen delivery, actively regulating the presentation of exogenous antigen proteins via the major histocompatibility complex (MHC-I) or MHC-II pathways. Immune data from in vivo mouse experiments indicated that the LIPO vaccine effectively stimulated both humoral and cellular immune responses. Furthermore, it triggers immune protection by establishing a robust and persistent germinal center. Moreover, the multifunctionality of this LIPO vaccine extends to the fields of cancer, viruses, and bacteria, providing insights for skilled vaccine design and improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.
- Jinhua Institute of Zhejiang University, 403 Yongkang Street, Jinhua 321299, China.
- Key Laboratory for Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.
- The First Affiliated Hospital Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310009, China.
ORCID-Profile: Jian You
Förderung
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
- Zhejiang Province Public Welfare Technology Application Research Project
- National Natural Science Foundation of China
Zitieren
APA
Luo, L., Luo, Z., Wang, L., Hu, Y., Zhang, J., Yin, H., & You, J. (2023). Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00536
Vancouver
Luo L, Luo Z, Wang L, Hu Y, Zhang J, Yin H, et al. Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00536
BibTeX
@article{Luo2023,
author = {Luo, Lihua and Luo, Zhenyu and Wang, Litong and Hu, Yilong and Zhang, Junlei and Yin, Hang and You, Jian},
title = {Liposome Vaccine for Active Regulation of Cellular and Humoral Immunity},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00536}
}
EUVIMED